Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S K Gilbert

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Science Signaling|July 18, 2019
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancerDevon R Blake, Angelina V Vaseva, Richard G Hodge, et al.
ACS Chemical Biology|April 26, 2019
Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related AnaloguesPaul R Graves, Lucas J Aponte-Collazo, Emily M J Fennell, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 10, 2018
Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell GrowthLinas J Krulikas, Ian M McDonald, Benjamin Lee, et al.
The Journal of Biological Chemistry|October 24, 2021
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancerJ Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, et al.
Journal of Proteome Research|August 27, 2023
Investigation of the Host Kinome Response to Coronavirus Infection Reveals PI3K/mTOR Inhibitors as Betacoronavirus AntiviralsEthan J Fritch, Angie L Mordant, Thomas S K Gilbert, et al.
Journal of the American Chemical Society|September 10, 2019
Data-Driven Construction of Antitumor Agents with Controlled PolypharmacologyChenxiao Da, Dehui Zhang, Michael Stashko, et al.
Cancer Cell|November 14, 2018
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory MechanismAngelina V Vaseva, Devon R Blake, Thomas S K Gilbert, et al.
Cell Reports|June 20, 2020
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, et al.
Cell Reports|June 30, 2021
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibitionAndrew M Waters, Tala O Khatib, Bjoern Papke, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Science Signaling|July 18, 2019
Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancerDevon R Blake, Angelina V Vaseva, Richard G Hodge, et al.
ACS Chemical Biology|April 26, 2019
Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related AnaloguesPaul R Graves, Lucas J Aponte-Collazo, Emily M J Fennell, et al.
SLAS Discovery : Advancing Life Sciences R & D|May 10, 2018
Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell GrowthLinas J Krulikas, Ian M McDonald, Benjamin Lee, et al.
The Journal of Biological Chemistry|October 24, 2021
The KRAS-regulated kinome identifies WEE1 and ERK coinhibition as a potential therapeutic strategy in KRAS-mutant pancreatic cancerJ Nathaniel Diehl, Jennifer E Klomp, Kayla R Snare, et al.
Journal of Proteome Research|August 27, 2023
Investigation of the Host Kinome Response to Coronavirus Infection Reveals PI3K/mTOR Inhibitors as Betacoronavirus AntiviralsEthan J Fritch, Angie L Mordant, Thomas S K Gilbert, et al.
Journal of the American Chemical Society|September 10, 2019
Data-Driven Construction of Antitumor Agents with Controlled PolypharmacologyChenxiao Da, Dehui Zhang, Michael Stashko, et al.
Cancer Cell|November 14, 2018
KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory MechanismAngelina V Vaseva, Devon R Blake, Thomas S K Gilbert, et al.
Cell Reports|June 20, 2020
Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant CancersIrem Ozkan-Dagliyan, J Nathaniel Diehl, Samuel D George, et al.
Cell Reports|June 30, 2021
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibitionAndrew M Waters, Tala O Khatib, Bjoern Papke, et al.
Plos One|July 15, 2021
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALKLong-Sheng Chang, Janet L Oblinger, Abbi E Smith, et al.
Pageof 2